Home › Acute Myeloid Leukemia › North Carolina › Durham
Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa Durham, NC
Isang pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Durham. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Nagre-recruitPhase 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Durham VA Medical Center, Durham
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Nagre-recruitPhase 2
- Duke University Medical Center, Durham
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Nagre-recruitPhase 2
- Duke University Medical Center, Durham
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Nagre-recruitPhase 2
- Duke University Medical Center, Durham
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Nagre-recruitPhase 2
- Duke University Medical Center, Durham
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Nagre-recruitPhase 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Nagre-recruitPhase 1/2
- Duke University Medical Center, Durham
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Nagre-recruitPhase 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi ang layo
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Nagre-recruitPhase 1/2
- UNC School of Medicine, Division of Hematology, Chapel Hill · 10 mi ang layo
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Nagre-recruitPhase 3
- US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill · 10 mi ang layo
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Nagre-recruitPhase 1/2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Nagre-recruitPhase 1
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Nagre-recruitPhase 3
- Duke University Medical Center, Durham
- University of North Carolina, Chapel Hill, Chapel Hill · 10 mi ang layo
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Nagre-recruitPhase 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi ang layo
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Nagre-recruitPhase 1/2
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi ang layo
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Nagre-recruitPhase 2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi ang layo
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Nagre-recruitObservasyonal na pag-aaral
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi ang layo
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
Nagre-recruit
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
Registry of Older Patients With Cancer
Nagre-recruitObservasyonal na pag-aaral
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi ang layo
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Nagre-recruitPhase 2
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · 10 mi ang layo
A Study of Revumenib and Mezigdomide in People With Leukemia
Nagre-recruitPhase 1/2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi ang layo
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Nagre-recruitPhase 1
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · 10 mi ang layo
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Nagre-recruitPhase 1
- University of North Carolina, Chapel Hill · 10 mi ang layo
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Nagre-recruitPhase 2/3
- Duke University, Durham
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Nagre-recruitPhase 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi ang layo
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Nagre-recruitPhase 2
- University of North Carolina, Chapel Hill · 10 mi ang layo
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Nagre-recruitPhase 1
- Duke Blood Cancer Center, Durham
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Nagre-recruitPhase 1
- Duke Cancer Center, Durham
Novel Digital Application for Patients With Acute Leukemia
Nagre-recruit
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Nagre-recruitObservasyonal na pag-aaral
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi ang layo
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Nagre-recruitPhase 1/2
- Duke University Medical Center, Durham
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Duke University, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi ang layo
Pag-aaral para sa Acute Myeloid Leukemia sa ibang lungsod
- Houston, TX85 pag-aaral
- New York City, NY51 pag-aaral
- Boston, MA44 pag-aaral
- Seattle, WA41 pag-aaral
- Baldwin Park, CA40 pag-aaral
- Columbus, OH35 pag-aaral
- Philadelphia, PA34 pag-aaral
- Atlanta, GA31 pag-aaral
- Tampa, FL29 pag-aaral
- Chicago, IL26 pag-aaral
- Portland, OR25 pag-aaral
- Washington, DC24 pag-aaral
Iba pang pag-aaral sa Durham
- Kanser sa Suso64 pag-aaral
- Kanser (lahat ng uri)58 pag-aaral
- Non-Small Cell Lung Cancer39 pag-aaral
- Multiple Myeloma37 pag-aaral
- Metastatic Cancer33 pag-aaral
- Kanser sa Prostate32 pag-aaral
- Kanser sa Baga32 pag-aaral
- Colorectal Cancer28 pag-aaral
- Kanser sa Ovary27 pag-aaral
- Chronic Lymphocytic Leukemia27 pag-aaral
- Pagkabigo ng Puso26 pag-aaral
- Kanser sa Pancreas24 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.